BioSpace News Archive

TRACON Pharmaceuticals announced today that the U.S. Food and Drug Administration (FDA) has granted TRACON a Type B Teleconference to take place on May 8, 2020

CAE announced today that it has taken a series of flexible measures to protect its financial position in response to the COVID-19 crisis and mitigate the impact on its employees.

Today, OpenMed, Inc. (www.openmed.com), announced the launch of the “Corona Checker” App on iOS App Store and “OpenMed Checker” on Google Play - the first-ever AI symptom evaluator coupled with coordinated definitive testing through a significant network of CLIA certified labs and medical professionals to provide test sampling, for qualified users.

Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, today announced that, due to the evolving COVID-19 pandemic and related customer impact, it is withdrawing 2020 annual guidance, which was provided on January 30, 2020 . Thermo Fisher has mobilized to support the global COVID-19 response with produc

BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) today announced that based on recent meetings with health authorities in the US and Europe , the Company plans to submit marketing applications to the US

Tyme Technologies, Inc. (NASDAQ: TYME), an emerging biotechnology company developing cancer metabolism-based therapies (CMBTs™), announced that management will present at the 2020 Cross-Border Healthcare Webinar Series on Tuesday, April 7, 2020.

Presentation to be webcast on Cortexyme’s website --

American BriVision (Holding) Corporation (OTCQB: ABVC) (the “Company”), a clinical stage biopharmaceutical company developing therapeutic solutions in oncology/hematology, CNS and ophthalmology, today announced that a site monitoring visit was conducted on March 10 and March 11, 2020 at the University of California San Francisco (UCSF) Medical Center for ABV-1505 Phase II Part I clinical trial,

OncoSec Medical Incorporated (NASDAQ:ONCS) (the “Company” or “OncoSec”), a company developing late-stage intratumoral DNA‑based cancer immunotherapies, today announced that Providence Cancer Institute, a part of Providence St. Joseph Health (“Providence”), is pursuing a first-in-human Phase 1 clinical trial of OncoSec’s novel DNA‑encodable, investigational vaccine, CORVax12,

Natera, Inc., a pioneer and global leader in cell-free DNA testing and non-invasive prenatal testing announced an expansion in coverage of its Panorama test to all pregnant women, regardless of age, after a major national insurance company expanded coverage of NIPT temporarily.